MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 466047 | Name: ABT-107

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ABT-107 is an α7 nicotinic receptor agonist. ABT-107 strongly suppressed the activation of NF-κB in progranulin-deficient cells. Treatment with ABT-107 also reduced microgliosis, decreased TNFα levels, and reduced compulsive behavior in progranulin-deficient mice.

Chemical Structure

ABT-107
ABT-107
CAS#855291-54-2

Theoretical Analysis

MedKoo Cat#: 466047

Name: ABT-107

CAS#: 855291-54-2

Chemical Formula: C19H20N4O

Exact Mass: 320.1637

Molecular Weight: 320.40

Elemental Analysis: C, 71.23; H, 6.29; N, 17.49; O, 4.99

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
ABT-107; ABT107; ABT 107;
IUPAC/Chemical Name
3-((6-(1H-indol-5-yl)pyridazin-3-yl)oxy)quinuclidine
InChi Key
LUKNJAQKVPBDSC-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H20N4O/c1-2-16-15(5-8-20-16)11-14(1)17-3-4-19(22-21-17)24-18-12-23-9-6-13(18)7-10-23/h1-5,8,11,13,18,20H,6-7,9-10,12H2
SMILES Code
N12CCC(C(OC3=NN=C(C4=CC5=C(NC=C5)C=C4)C=C3)C2)CC1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 320.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Minami SS, Shen V, Le D, Krabbe G, Asgarov R, Perez-Celajes L, Lee CH, Li J, Donnelly-Roberts D, Gan L. Reducing inflammation and rescuing FTD-related behavioral deficits in progranulin-deficient mice with α7 nicotinic acetylcholine receptor agonists. Biochem Pharmacol. 2015 Oct 15;97(4):454-462. doi: 10.1016/j.bcp.2015.07.016. Epub 2015 Jul 20. PMID: 26206194; PMCID: PMC4859338. 2: Kohlhaas KL, Robb HM, Roderwald VA, Rueter LE. Nicotinic modulation of auditory evoked potential electroencephalography in a rodent neurodevelopmental model of schizophrenia. Biochem Pharmacol. 2015 Oct 15;97(4):482-487. doi: 10.1016/j.bcp.2015.05.011. Epub 2015 May 29. PMID: 26032639. 3: Yildirim E, Connor DA, Gould TJ. ABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice. Behav Pharmacol. 2015 Apr;26(3):241-8. doi: 10.1097/FBP.0000000000000111. PMID: 25426579; PMCID: PMC4459497. 4: Bordia T, McGregor M, Papke RL, Decker MW, McIntosh JM, Quik M. The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions. Exp Neurol. 2015 Jan;263:277-84. doi: 10.1016/j.expneurol.2014.09.015. Epub 2014 Sep 28. PMID: 25261754; PMCID: PMC4262739. 5: Lee AM, Arreola AC, Kimmey BA, Schmidt HD. Administration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the reinstatement of nicotine-seeking behavior in rats. Behav Brain Res. 2014 Nov 1;274:168-75. doi: 10.1016/j.bbr.2014.08.016. Epub 2014 Aug 14. PMID: 25128791; PMCID: PMC4179987. 6: Zhang D, McGregor M, Decker MW, Quik M. The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys. J Pharmacol Exp Ther. 2014 Oct;351(1):25-32. doi: 10.1124/jpet.114.216283. Epub 2014 Jul 17. PMID: 25034405; PMCID: PMC4165030. 7: Zhang D, McGregor M, Bordia T, Perez XA, McIntosh JM, Decker MW, Quik M. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Mov Disord. 2015 Dec;30(14):1901-1911. doi: 10.1002/mds.26453. Epub 2015 Nov 17. PMID: 26573698; PMCID: PMC4715565. 8: Yohn NL, Turner JR, Blendy JA. Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors. J Pharmacol Exp Ther. 2014 May;349(2):348-54. doi: 10.1124/jpet.113.211706. Epub 2014 Mar 13. PMID: 24627467; PMCID: PMC3989801. 9: Gannon RL, Garcia DA, Millan MJ. Effects of systemically applied nAChRα7 agonists and antagonists on light-induced phase shifts of hamster circadian activity rhythms. Eur Neuropsychopharmacol. 2014 Jun;24(6):964-73. doi: 10.1016/j.euroneuro.2013.12.007. Epub 2013 Dec 17. PMID: 24388152. 10: Liu H, Deng X, Liu J, Liu N, Stuart P, Xu H, Guan Z, Marsh KC, De Morais SM. Species-dependent metabolism of a novel selective α7 neuronal acetylcholine receptor agonist ABT-107. Xenobiotica. 2013 Sep;43(9):803-16. doi: 10.3109/00498254.2012.760763. Epub 2013 Jan 18. PMID: 23327533. 11: Radek RJ, Robb HM, Stevens KE, Gopalakrishnan M, Bitner RS. Effects of the novel α7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA/2 mice: pharmacodynamic characterization. J Pharmacol Exp Ther. 2012 Dec;343(3):736-45. doi: 10.1124/jpet.112.197970. Epub 2012 Sep 17. PMID: 22988063. 12: Pohanka M. Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. Int J Mol Sci. 2012;13(2):2219-38. doi: 10.3390/ijms13022219. Epub 2012 Feb 17. PMID: 22408449; PMCID: PMC3292018. 13: Kohlhaas KL, Bitner RS, Gopalakrishnan M, Rueter LE. Effects of α7 nicotinic acetylcholine receptor agonists on antipsychotic efficacy in a preclinical mouse model of psychosis. Psychopharmacology (Berl). 2012 Apr;220(4):823-33. doi: 10.1007/s00213-011-2535-6. Epub 2011 Oct 29. PMID: 22038534. 14: Malysz J, Anderson DJ, Grønlien JH, Ji J, Bunnelle WH, Håkerud M, Thorin- Hagene K, Ween H, Helfrich R, Hu M, Gubbins E, Gopalakrishnan S, Puttfarcken PS, Briggs CA, Li J, Meyer MD, Dyhring T, Ahring PK, Nielsen EØ, Peters D, Timmermann DB, Gopalakrishnan M. In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107. J Pharmacol Exp Ther. 2010 Sep 1;334(3):863-74. doi: 10.1124/jpet.110.167072. Epub 2010 May 26. PMID: 20504915. 15: Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, Marsh KC, Nikkel AL, Browman K, Radek R, Anderson DJ, Buccafusco J, Gopalakrishnan M. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J Pharmacol Exp Ther. 2010 Sep 1;334(3):875-86. doi: 10.1124/jpet.110.167213. Epub 2010 May 26. PMID: 20504913. 16: Othman AA, Lenz RA, Zhang J, Li J, Awni WM, Dutta S. Single- and multiple- dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers. J Clin Pharmacol. 2011 Apr;51(4):512-26. doi: 10.1177/0091270010370460. Epub 2010 May 21. PMID: 20495134.

View History

Proxifezone

Proxifezone